Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in developing adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinsons disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a worldwide licensing agreement with Ramot, the technology transfer company of the Tel Aviv University.
BCLI's NurOwn technology, an autologous adult stem cell therapy technology that differentiates bone marrow-derived mesenchymal stem cells into specialized neuron-supporting cells. It also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center.
Brainstorm Cell Therapy was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. BCLI was founded in 2000 and is based in New York, New York.
January 10, 2023
RegMed Investors’ (RMi) pre-open: after a lackluster first day at JPM23 with smaller attendance, NO masks and a diving sector
January 9, 2023
RegMed Investors’ (RMi) closing bell: JPM23 rippled share pricing with most positive equities inching upward
January 4, 2023
RegMed Investors’ (RMi) closing bell: sector churns higher
December 23, 2022
RegMed Investors’ (RMi) closing bell: low liquidity and thin volume
December 22, 2022
RegMed Investors’ (RMi) closing bell: selling returned Thursday
December 14, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector craters as Fed rate decision unfolds with more hikes next year
December 13, 2022
RegMed Investors’ (RMi) closing bell: indexes slow and some sector gains evaporate post CPI release
December 12, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector opened and closed higher as oversold were “recognized” in-front of CPI and Fed meeting report
December 8, 2022
RegMed Investors’ (RMi) closing bell: sector share pricing rise, not due to investors but, electronic trading and algorithms
December 2, 2022
RegMed Investors’ (RMi) closing bell: The sector is what it is until it isn’t and even then, it doesn’t seem to be
35 companies, 1 interpreter!
Insight, foresight and recommendation
Brainstorm Cell Therapeutics (BCLI) – January '18 openaed at $3.65, dropping in February to $3.45 and continuing to drop to $3.10 on 2/12 and $3.19 on 2/16. Even with their on-going trial, I have a problem with theor corporate transparency ... tey revolve on news and the pricing falls back ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.